报告期内，公司与辉瑞公司(PfizerInc.)达成重要合作;公司收到辉瑞公司就707项目支付的授权许可首付 款并相应确认收入约28.90亿元人民币，导致2025年度的营业收入、归属于母公司所有者的净利润以及 扣除非经常损益后归属于母公司所有者的净利润均出现较大幅度的增长。 三生国健（688336）(688336.SH)发布2025年年度业绩预告，公司2025年度预计实现归属于母公司所有 者的净利润29亿元左右，与上年同期相比，将增加21.95亿元左右，相比上年同期涨幅约311.35%。 预计实现归属于母公司所有者的扣除非经常性损益后的净利润28亿元左右，与上年同期相比，将增加 25.54亿元左右，相比上年同期涨幅约1,038.21%。 ...

人民财讯1月26日电，三生国健(688336)1月26日公告，经财务部门初步测算，2025年度预计实现营业收 入42亿元左右，与上年同期相比，同比增长约251.76%。预计实现归属于母公司所有者的净利润29亿元 左右，与上年同期相比，同比增长约311.35%。报告期内，公司与辉瑞公司达成重要合作；公司收到辉 瑞公司就707项目支付的授权许可首付款并相应确认收入约28.9亿元人民币。 ...

每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经AI快讯，三生国健1月26日晚间发布业绩预告，公司2025年度预计实现归属于母公司所有者的净利 润29亿元左右，与上年同期相比，将增加21.95亿元左右，相比上年同期涨幅约311.35%。业绩变动主要 原因是，报告期内，公司与辉瑞公司达成重要合作；公司收到辉瑞公司就707项目支付的授权许可首付 款并相应确认收入约28.9亿元人民币，导致2025年度的营业收入、归属于母公司所有者的净利润以及扣 除非经常损益后归属于母公司所有者的净利润均出现较大幅度的增长。 每日经济新闻 （记者 王晓波） ...

据计算，Q4净利润预计25.01亿元，环比增长1097%。第四季度净利润分析师一致预测是18.63亿，业绩 高于预期。 格隆汇1月26日｜三生国健(688336.SH)发布2025年年度业绩预告，预计归属于上市公司股东的净利润为 29.00亿元左右，比上年同期增长311.35%。报告期内，公司与辉瑞公司（PfizerInc.）达成重要合作；公 司收到辉瑞公司就707项目支付的授权许可首付款并相应确认收入约28.90亿元人民币，导致2025年度的 营业收入、归属于母公司所有者的净利润以及扣除非经常损益后归属于母公司所有者的净利润均出现较 大幅度的增长。 ...

三生国健(688336.SH)发布2025年年度业绩预告，预计归属于上市公司股东的净利润为29.00亿元左右， 比上年同期增长311.35%。报告期内，公司与辉瑞公司（PfizerInc.）达成重要合作；公司收到辉瑞公司 就707项目支付的授权许可首付款并相应确认收入约28.90亿元人民币，导致2025年度的营业收入、归属 于母公司所有者的净利润以及扣除非经常损益后归属于母公司所有者的净利润均出现较大幅度的增长。 ...

格隆汇1月26日丨三生国健(688336.SH)公布，经财务部门初步测算，2025年度预计实现营业收入42.00亿 元左右，与上年同期相比，将增加30.06亿元左右，相比上年涨幅约251.76%。公司2025年度预计实现归 属于母公司所有者的净利润29.00亿元左右，与上年同期相比，将增加21.95亿元左右，相比上年同期涨 幅约311.35%。公司2025年度预计实现归属于母公司所有者的扣除非经常性损益后的净利润28.00亿元左 右，与上年同期相比，将增加25.54亿元左右，相比上年同期涨幅约1,038.21%。 报告期内，公司与辉瑞公司（Pfizer Inc.）达成重要合作；公司收到辉瑞公司就707项目支付的授权许可 首付款并相应确认收入约28.90亿元人民币，导致2025年度的营业收入、归属于母公司所有者的净利润 以及扣除非经常损益后归属于母公司所有者的净利润均出现较大幅度的增长。 ...

Core Viewpoint - Sanofi Guojian (688336.SH) forecasts a significant increase in net profit for 2025, projecting approximately 2.9 billion yuan, representing a year-on-year growth of 311.35% [1] Financial Performance - The company expects substantial growth in operating revenue and net profit attributable to shareholders due to a key collaboration with Pfizer Inc. [1] - The revenue recognized from Pfizer for the 707 project is approximately 2.89 billion yuan, contributing to the anticipated increase in financial metrics for 2025 [1]

Core Viewpoint - Sanofi Guojian (688336.SH) is expected to see significant growth in revenue and net profit for the fiscal year 2025, driven by a key collaboration with Pfizer and substantial income from licensing agreements [1] Financial Projections - The company anticipates achieving approximately 4.2 billion yuan in operating revenue for 2025, an increase of about 3.006 billion yuan compared to the previous year, representing a growth rate of approximately 251.76% [1] - The projected net profit attributable to the parent company for 2025 is around 2.9 billion yuan, which is an increase of about 2.195 billion yuan year-on-year, reflecting a growth rate of approximately 311.35% [1] - The expected net profit attributable to the parent company after deducting non-recurring gains and losses is estimated at about 2.8 billion yuan, with an increase of approximately 2.554 billion yuan compared to the previous year, indicating a staggering growth rate of about 1,038.21% [1] Strategic Partnerships - The company has established a significant collaboration with Pfizer, which has resulted in the receipt of an upfront payment for the 707 project, contributing approximately 2.89 billion yuan to the recognized revenue [1]

Revenue Projections - The company expects to achieve approximately CNY 4.2 billion in revenue for the year 2025, an increase of about CNY 3.006 billion compared to the previous year, representing a growth rate of approximately 251.76%[5] Profit Projections - The projected net profit attributable to the parent company for 2025 is around CNY 2.9 billion, which is an increase of approximately CNY 2.195 billion year-over-year, reflecting a growth rate of about 311.35%[5] - The expected net profit attributable to the parent company after deducting non-recurring gains and losses is approximately CNY 2.8 billion, an increase of about CNY 2.554 billion compared to the previous year, indicating a growth rate of approximately 1,038.21%[5] - The previous year's net profit attributable to the parent company was CNY 705 million, with a net profit after deducting non-recurring gains and losses of CNY 246 million[8] Contributing Factors - A significant factor contributing to the performance increase is the collaboration with Pfizer Inc., which resulted in a licensing fee payment of approximately CNY 2.89 billion recognized as revenue[10] Financial Reporting - The earnings forecast has not been audited by a registered accountant, and the company assures that there are no major uncertainties affecting the accuracy of this forecast[12] - The data provided is preliminary and the final audited financial data will be disclosed in the official 2025 annual report[13]

Group 1 - The core viewpoint of the news highlights the performance of the medical innovation sector, with the China Securities Medical and Medical Device Innovation Index (931484) rising by 0.51% and notable increases in constituent stocks such as Ganli Pharmaceutical (3.05%) and Zhejiang Pharmaceutical (2.29%) [1] - The Medical Innovation ETF (516820) has seen a net inflow of funds over the past five days, with a peak single-day net inflow of 40.537 million yuan, totaling 62.4623 million yuan, averaging a daily net inflow of 12.4925 million yuan [1] - Baichuan Intelligent has launched the Baichuan-M3 Plus evidence-enhanced medical model, achieving a hallucination rate of 2.6%, the lowest globally, and introduced the "Evidence Anchoring" technology to provide citation sources for medical conclusions [1] Group 2 - Everbright Securities emphasizes that the AI+ healthcare sector should focus on several core areas: AI drug development, AI medical imaging, AI chronic disease management, and AI surgical robots, highlighting the strong willingness of pharmaceutical companies to invest in AI drug development due to its potential to significantly shorten drug development cycles [2] - The China Securities Medical and Medical Device Innovation Index selects 30 publicly listed companies with good profitability and growth potential from the pharmaceutical and healthcare sector, reflecting the overall performance of profitable and growth-oriented companies [2] - As of December 31, 2025, the top ten weighted stocks in the index include WuXi AppTec, Hengrui Medicine, Mindray Medical, and others, accounting for 63.75% of the total index weight [2]